Novel Selective MAO-B Inhibitors From Hispidol Analogues

Why It Matters

Selective MAO‑B inhibition can slow dopamine loss in Parkinson's disease without the side effects linked to non‑selective inhibitors, opening a clearer path to disease‑modifying therapies.

Key Takeaways

• Hispidol analogues show sub‑micromolar MAO‑B inhibition
• Selectivity over MAO‑A exceeds 100‑fold
• In vivo models improve motor function in Parkinsonian mice
• Favorable ADME profile suggests drug‑like properties

Pulse Analysis

Monoamine oxidase‑B (MAO‑B) has long been a therapeutic target for Parkinson's disease and other neurodegenerative conditions, yet existing drugs often suffer from limited selectivity and adverse interactions. Natural flavonoid hispidol, known for its antioxidant activity, provides a versatile scaffold for medicinal chemists seeking to fine‑tune enzyme inhibition. By systematically modifying the phenolic and prenyl groups, the research team generated a library of analogues that retained the core scaffold while enhancing binding affinity for the MAO‑B active site. This approach leverages structure‑based design to overcome the classic trade‑off between potency and safety.

The most potent analogue, designated HSD‑B12, inhibits MAO‑B with an IC50 of 0.45 µM and demonstrates more than a 100‑fold selectivity margin over MAO‑A. In rodent models of Parkinsonism, oral administration of HSD‑B12 restored locomotor activity and reduced striatal oxidative stress, indicating functional brain penetration and target engagement. Pharmacokinetic studies revealed a half‑life of 6.2 hours, moderate plasma protein binding, and negligible CYP450 inhibition, suggesting a low risk of drug‑drug interactions. These data collectively support the compound’s drug‑like profile and its readiness for IND‑enabling toxicology.

If further development proceeds, selective MAO‑B inhibitors derived from hispidol could reshape the market for neuroprotective agents, which is projected to exceed $5 billion by 2030. The chemistry platform also offers a template for rapid diversification against other flavonoid‑based targets. Upcoming steps include GLP toxicology, formulation optimization, and early‑phase clinical trials to assess efficacy in patients with early‑stage Parkinson's disease. Success would not only validate the hispidol scaffold but also provide clinicians with a safer, more effective tool to manage disease progression.